Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 158

Sort by

Sort Order Select

Journal Articles

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1504.3.

https://doi.org/10.1182/blood-2024-205101

Published: 2024

Journal Articles

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

Areej El-Jawahri, Alison R Kavanaugh, Joseph A Greer, Vicki Jackson, Jillian Gustin, Alice Mims, Albert Cook, Thomas W. LeBlanc, Amir T. Fathi, Gabriela S. Hobbs, Andrew M. Brunner, Jennifer S Temel

Blood (2024) 144 (Supplement 1): 117.

https://doi.org/10.1182/blood-2024-209628

Published: 2024

Journal Articles

A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS

Amir T. Fathi, Aleksandra Filipovic, Keri Maher, Dale G Schaar, Rabin Niroula, Joseph J. Maly, Deepa Jaykumar, Noah Merin, Jay Yang, Jorge R. Galvez Silva, Varun Gang, Taylor Meeks, Christopher Korth, Guenther Koehne

Blood (2024) 144 (Supplement 1): 1499.

https://doi.org/10.1182/blood-2024-209848

Published: 2024

Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Blood (2024) 144 (Supplement 1): 221.

https://doi.org/10.1182/blood-2024-201595

Published: 2024

Journal Articles

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 2880.

https://doi.org/10.1182/blood-2024-199170

Published: 2024

Journal Articles

Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy

Gabrielle T. Prince, Praneeth Baratam, Guillermo Garcia-Manero, Anne Angiolillo, Tarun Bhagnani, Assaf Vestin, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 3226.

https://doi.org/10.1182/blood-2024-209071

Published: 2024

Journal Articles

Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction

Michelle Hyunju Lee, Wyatt McCall, Joanna Cwykiel, Chenyu Lin, Ellen Madarang, Justin M. Watts, Harry P. Erba, Yasmin Abaza, Alexander E. Perl, Andrew H Matthews, Andrew M. Brunner, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2024-205931

Published: 2024

Journal Articles

Impact of Ultra Rapid Molecular Profiling on Treatment Delays and Healthcare Utilization of Patients Hospitalized for Acute Leukemia

Tejaswini Dhawale, Valentina Nardi, Charlotte Wang, Adam Bard, Natalia Essigmann, Daniel Leonard, Timothy Aaron Graubert, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 5058.

https://doi.org/10.1182/blood-2024-208059

Published: 2024

Journal Articles

Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

Blood (2024) 144 (Supplement 1): 4256.

https://doi.org/10.1182/blood-2024-200876

Published: 2024

Journal Articles

Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Naval Daver, Naveen Pemmaraju, Mikkael A. Sekeres, Amir T. Fathi, Andrew A. Lane, Anna Compagnoni, Ira Gupta, Alessandra Tosolini, Jessica Garzon, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 4265.1.

https://doi.org/10.1182/blood-2024-193593

Published: 2024

Journal Articles

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Andrew M. Brunner, Yiwen Liu, Jacqueline S. Garcia, Lourdes Mendez, Catherine Gutierrez, Philip C. Amrein, Rupa Narayan, Rahul Vedula, Donna S. Neuberg, Marcio Andrade-Campos, Simon Smith, Richard M Stone, Amir T. Fathi, Matthew J. Walter, Timothy Aaron Graubert, Meagan Jacoby

Blood (2024) 144 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2024-195793

Published: 2024

Journal Articles

Retrospective Single-Institution Review of Bosutinib Dose Optimization for Efficacy and Safety with Dose Ramp-up and Titration

Jessica Freydman, David Sirignano, Philip C. Amrein, Meghan Bergeron, Andrew M. Brunner, Elsie Foster, Amir T. Fathi, Timothy Aaron Graubert, Hanno Hock, Michelle Hyunju Lee, Jenna Moran, Rupa Narayan, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6591.

https://doi.org/10.1182/blood-2024-203629

Published: 2024

Journal Articles

TRK Protein Expression in TP53 Altered Acute Erythroid Leukemia

Rupa Narayan, Ronan T. Swords, Philip C. Amrein, Andrew M. Brunner, Gabriela S. Hobbs, Hanno Hock, Michelle Hyunju Lee, Timothy Aaron Graubert, Amir T. Fathi, Robert P Hasserjian, Valentina Nardi

Blood (2024) 144 (Supplement 1): 6154.

https://doi.org/10.1182/blood-2024-211201

Published: 2024

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Response in Patients with Chronic Myelogenous Leukemia (CML) and BCR-ABL 35 Base Pair Intron 8 Insertion (35INS)

Roxana A Portillo, Michelle Hyunju Lee, Harrison K. Tsai, Daniel J DeAngelo, Amir T. Fathi, Rupa Narayan, Marlise R Luskin, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6598.

https://doi.org/10.1182/blood-2024-206655

Published: 2024

Journal Articles

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

Andrew M. Brunner, Yiwen Liu, Rupa Narayan, Michelle Hyunju Lee, Philip C. Amrein, Hanno Hock, Gabriela S. Hobbs, Donna S. Neuberg, Timothy Aaron Graubert, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 6726.

https://doi.org/10.1182/blood-2024-196718

Published: 2024

Journal Articles

Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (m IDH1 ) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria

Yazan F Madanat, Amir T. Fathi, Guillermo Garcia-Manero, Gail J. Roboz, Justin M. Watts, Gabrielle T. Prince, Praneeth Baratam, Stephane De Botton, Anthony S. Stein, James M. Foran, Martha L. Arellano, David Sallman, Yuanye (Vickie) Zhang, Stephanie M. Kapsalis, Prapti A. Patel, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2024-204862

Published: 2024

Journal Articles

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Nicole R. Grieselhuber, Praneeth Baratam, Anjali S. Advani, Abdulraheem Yacoub, Don A. Stevens, Ahmed Aribi, Ben K. Tomlinson, Jay Yang, Pankit Vachhani, Joseph G Jurcic, Caspian H. Oliai, Jessica Liegel, Edward Pearson, Anna Van Rhenen, Marcello Rotta, Kapil Rathi, Juan Pinelli, Tara Chen, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2024-199634

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 214.

https://doi.org/10.1182/blood-2024-198218

Published: 2024

Journal Articles

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Blood (2024) 144 (Supplement 1): 212.

https://doi.org/10.1182/blood-2024-207106

Published: 2024

NARROW

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy

Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction

Impact of Ultra Rapid Molecular Profiling on Treatment Delays and Healthcare Utilization of Patients Hospitalized for Acute Leukemia

Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Retrospective Single-Institution Review of Bosutinib Dose Optimization for Efficacy and Safety with Dose Ramp-up and Titration

TRK Protein Expression in TP53 Altered Acute Erythroid Leukemia

Tyrosine Kinase Inhibitor (TKI) Response in Patients with Chronic Myelogenous Leukemia (CML) and BCR-ABL 35 Base Pair Intron 8 Insertion (35INS)

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (m IDH1 ) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only